We selected the promyelocytic leukemia (APL)-driven NB4 cell line, which is highly responsive to differentiation therapy with all-trans retinoic acid (ATRA) [27] and which is relatively insensitive to TRAIL [28]. Here, TNFSF10 is linked to acute promyelocytic leukemia.